Loading…
LivaNova PLC is projected to rise to $110.03 by 2027, a +33% move from its current price of $82.56. LIVN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $81.56 | $82.62 | $83.70 | +0.08% |
| Jul 14 | $81.18 | $82.69 | $84.22 | +0.15% |
| Jul 15 | $80.91 | $82.75 | $84.63 | +0.23% |
| Jul 16 | $80.69 | $82.82 | $84.99 | +0.31% |
| Jul 17 | $80.51 | $82.88 | $85.32 | +0.39% |
| Jul 18 | $80.35 | $82.94 | $85.62 | +0.47% |
| Jul 19 | $80.21 | $83.01 | $85.91 | +0.54% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $80.21 | $83.01 | $85.91 | +0.54% |
| Week 2 | $79.50 | $83.46 | $87.61 | +1.09% |
| Week 3 | $79.07 | $83.91 | $89.05 | +1.64% |
| Week 4 | $78.77 | $84.37 | $90.36 | +2.19% |
| Week 5 | $78.56 | $84.83 | $91.59 | +2.74% |
| Week 6 | $78.41 | $85.29 | $92.77 | +3.30% |
| Week 7 | $78.31 | $85.75 | $93.90 | +3.86% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
LivaNova PLC is a medical technology company that designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products.
The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression. This segment also includes the development and clinical testing of LivaNova's aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and other medical institutions and healthcare providers.
The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
LivaNova PLC (LIVN) is a healthcare company currently trading at $79.94 per share. It has a market capitalization of $4.39B and ranks 1449 by market size. The stock sits in the Healthcare sector and is followed by investors for its dual focus on Cardiopulmonary and Neuromodulation solutions.
The 30-day forecast outlines near-term movement with a neutral stance in 2026, where the average price equals the current level. The forecast then envisions bullish momentum across subsequent years, with notable upside in the long term as averages rise toward multi-year highs.
A major floor 30.2% below — a decisive break under it would weaken the trend.
The nearest floor, 13.6% below — buyers have tended to step in here.
Price is pressing into resistance (1.8% away) — a breakout level to watch.
A major ceiling 11.4% above — clearing it would confirm fresh momentum.
Key LIVN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LIVN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $83.04 | Sell | $82.74 | Sell |
| MA 10 | $83.00 | Sell | $82.37 | Buy |
| MA 20 | $81.20 | Buy | $80.81 | Buy |
| MA 50 | $74.86 | Buy | $76.19 | Buy |
| MA 100 | $69.74 | Buy | $71.48 | Buy |
| MA 200 | $64.37 | Buy | $65.69 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.11 | Neutral |
| Stoch RSI (14) | 4.22 | Buy |
| CCI (20) | 50.35 | Neutral |
| Williams %R (14) | -27.48 | Info |
| MACD (12,26,9) | -0.26 | Sell |
| ROC (12) | 4.93 | Buy |
| Bollinger %B (20,2) | 0.68 | Neutral |
| Stochastic %K (14) | 72.52 | Neutral |
| TRIX (15) | 0.50 | Buy |
| Awesome (5,34) | 4.73 | Buy |
| Ultimate (7,14,28) | 61.32 | Neutral |
| Momentum (10) | 1.51 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 82.65 | Sell |
| ADX (14) | 32.16 | Buy |
| ATR (14) | 0.81 | Info |
The 30-day technical picture shows bullish sentiment overall, with RSI14 at 70 and the stock trading near a resistance level at $79.94 while showing support at $57.59. The SMA50 is $68.43 and the SMA200 is $62.01, indicating an upward drift from longer-term moving averages. The 30-day range spans from $70.22 to $91.00, placing the current price within that range and suggesting potential upside or pullback depending on near-term dynamics.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $57.59 | $82.56 | $113.51 | 0% | Neutral | |
| $90.12 | $110.03 | $140.47 | +33% | Bullish | |
| $100.70 | $125.27 | $164.25 | +52% | Bullish | |
| $111.57 | $140.93 | $188.71 | +71% | Bullish | |
| $112.23 | $143.68 | $195.86 | +74% | Bullish | |
| $127.57 | $165.31 | $228.90 | +100% | Bullish | |
| $158.15 | $207.26 | $291.07 | +151% | Bullish | |
| $172.35 | $228.24 | $324.69 | +176% | Bullish | |
| $190.05 | $254.19 | $365.92 | +208% | Bullish | |
| $199.20 | $268.95 | $391.48 | +226% | Bullish | |
| $318.47 | $448.46 | $684.08 | +443% | Bullish | |
| $549.65 | $830.11 | $1,357.31 | +905% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $57.59 | $82.56 | $101.14 | +0.00% |
| August 2026 | $75.76 | $88.69 | $106.08 | +7.42% |
| September 2026 | $75.32 | $88.59 | $106.79 | -0.11% |
| October 2026 | $75.68 | $89.39 | $108.46 | +0.90% |
| November 2026 | $77.67 | $92.06 | $112.31 | +2.98% |
| December 2026 | $77.85 | $92.57 | $113.51 | +0.55% |
Click any year to see its month-by-month LIVN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, LIVN could reach as high as $113.51, with a base case around $82.56 and support toward $57.59 — roughly 0% from $82.56. Price action looks broadly range-bound.
Expect LIVN to range from $90.12 to $140.47 through 2027. The $110.03 average target implies a +33% move from current prices. That is up +33% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The LIVN price prediction for 2028 points to an average of $125.27 (low $100.70, high $164.25) — a potential gain of +52% on today's $82.56. Momentum favours further upside here.
In 2029, LIVN is projected to trade between $111.57 and $188.71, averaging $140.93 — a potential gain of +71% from today's $82.56. That is up +12% on the projected 2028 average. Buyers look set to stay in control over this stretch.
LivaNova PLC's 2030 outlook centres on $143.68, within a $112.23 to $195.86 range. That is up +2% on the projected 2029 average. That marks a +74% change versus current levels. Momentum favours further upside here.
By 2031, LIVN could reach as high as $228.90, with a base case around $165.31 and support toward $127.57 — roughly +100% from $82.56. Buyers look set to stay in control over this stretch.
Expect LIVN to range from $158.15 to $291.07 through 2032. The $207.26 average target implies a +151% move from current prices. That is up +25% on the projected 2031 average. Momentum favours further upside here.
The LIVN price prediction for 2033 points to an average of $228.24 (low $172.35, high $324.69) — a potential gain of +176% on today's $82.56. Buyers look set to stay in control over this stretch.
In 2034, LIVN is projected to trade between $190.05 and $365.92, averaging $254.19 — a potential gain of +208% from today's $82.56. That is up +11% on the projected 2033 average. Momentum favours further upside here.
LivaNova PLC's 2035 outlook centres on $268.95, within a $199.20 to $391.48 range. That is up +6% on the projected 2034 average. That marks a +226% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, LIVN could reach as high as $684.08, with a base case around $448.46 and support toward $318.47 — roughly +443% from $82.56. Momentum favours further upside here.
Expect LIVN to range from $549.65 to $1,357.31 through 2050. The $830.11 average target implies a +905% move from current prices. That is up +85% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in LIVN today (≈ 12.112403 LIVN) could be worth
$10,054.57
+$9,054.57 (+905%) by 2050 · US Dollar
Based on the average projected LIVN price of $830.11 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LIVNwould be worth at today's price.
$1,000 invested in LIVN on Jul 10, 2025 (≈ 21.427042 LIVN) would be worth
$1,769.02
+$769.02 (+76.9%) today · 1.77× · US Dollar
Based on a LIVN entry price of $46.67 vs. today's $82.56.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $83.62 | $987.32 | -1.3% |
| 1 month ago | $78.38 | $1,053.33 | +5.3% |
| 3 months ago | $62.78 | $1,315.07 | +31.5% |
| 6 months ago | $62.38 | $1,323.5 | +32.4% |
| 1 year ago | $46.67 | $1,769.02 | +76.9% |
| All time (5.0y) ago | $79.15 | $1,043.08 | +4.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LIVN forecast.
Our base-case forecast reaches $170.00 around 2032.
Implied market cap at $170.00: $9.34B
The multi-year forecast points to continued upside after 2026. In 2027, the average price is projected at $110.68 with a max of $142.22 and a min of $90.24, yielding a 38.5% ROI and a bullish outlook. By 2030, the average is $143.44 with a max of $197.07 and a min of $111.37, corresponding to a 79.4% ROI and a bullish sentiment.
The forecast continues to rise through 2040, with an average of $437.70, a min of $307.58, a max of $675.08, and a 447.5% ROI, maintaining a bullish stance. By 2050, the average reaches $798.79, the min is $521.40, the max is $1,323.27, and the ROI is 899.2%, with the sentiment remaining bullish. These figures illustrate substantial potential upside over the long horizon, while also underscoring that the projections are estimates and not guarantees.
Tap a question to reveal the answer.
2030: avg $143.44, min $111.37, max $197.07, ROI 79.4%, sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising average prices (e.g., 2027 avg $110.68, 2030 avg $143.44, 2040 avg $437.70, 2050 avg $798.79). 2026 is neutral with avg $79.94. Remember these are estimates, not guarantees.
Yes in the forecast the 2050 max is $1,323.27, which exceeds $1,000, indicating the path allows reaching that level under the projection; this is not a guarantee.
Current price $79.94; market cap $4.39B.
30-day range low $70.22; high $91.00.
LivaNova PLC Community Discussion
0Share your LivaNova PLC price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.